A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
about
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A randomized phase II study of ...... ancer: the AFUGEM GERCOR trial
@ast
A randomized phase II study of ...... ancer: the AFUGEM GERCOR trial
@en
type
label
A randomized phase II study of ...... ancer: the AFUGEM GERCOR trial
@ast
A randomized phase II study of ...... ancer: the AFUGEM GERCOR trial
@en
prefLabel
A randomized phase II study of ...... ancer: the AFUGEM GERCOR trial
@ast
A randomized phase II study of ...... ancer: the AFUGEM GERCOR trial
@en
P2093
P2860
P50
P1433
P1476
A randomized phase II study of ...... ancer: the AFUGEM GERCOR trial
@en
P2093
Benoist Chibaudel
Christophe Louvet
Franck Bonnetain
GERCOR group
Pierre Validire
P2860
P2888
P356
10.1186/S12885-015-1656-4
P407
P577
2015-10-06T00:00:00Z
P5875
P6179
1022436710